Court Rejects J&J Bid For Injunction In Amgen Case

Law360, New York (November 23, 2006, 12:00 AM EST) -- A federal judge in New Jersey has rejected Johnson & Johnson's request for a preliminary injunction against Amgen's marketing practices for anemia drug Aranesp in the ongoing antitrust battle between the two life-sciences giants.

On Wednesday, U.S. District Court Judge Stanley Chesler denied a request from the Johnson & Johnson Inc. biotech unit Ortho Biotech Products to block rebate contracts that encourage doctors to use the anemia treatment Aranesp when they use Neupogen or Neulasta, two Amgen drugs used to prevent infections in chemotherapy patients....
To view the full article, register now.